Skip to main content
Premium Trial:

Request an Annual Quote

Ingenium Signs Agreements with Max-Planck and GSF

NEW YORK, Dec. 19 (GenomeWeb News) - Ingenium Pharmaceuticals announced today that it had signed two partnership agreements - one with the Max Planck Institute of Immunology in Freiburg, Germany; and one with the German National Research Center for Environment and Health (GSF).


The Max Planck agreement involves Ingenium's Ingenotyping platform. Ingenium will provide genetic mouse models for target genes to Max Planck using Ingenotyping, a high-speed in vivo target validation tool.


The GSF agreement involves an in-licensing agreement to create the world's largest sperm archive for murine models, according to the company.


Financial terms of the agreements were not disclosed.


The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.